Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.

Autor: Iriarte C; Department of Dermatology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Gryzmish 522, Boston, MA, 02215, USA. ciriarte@bidmc.harvard.edu.; Department of Dermatology, Harvard Medical School, Boston, MA, USA. ciriarte@bidmc.harvard.edu., Yeh JE; Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA., Alloo A; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA., Boull C; Department of Dermatology, University of Minnesota, Minneapolis, MN, USA., Carlberg VM; Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA.; Children's Wisconsin, Milwaukee, WI, USA., Coughlin CC; Division of Dermatology, Departments of Medicine and Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Lara-Corrales I; Division of Dermatology, Hospital for Sick Children, Toronto, ON, Canada.; University of Toronto, Toronto, ON, Canada., Levy R; Division of Dermatology, Hospital for Sick Children, Toronto, ON, Canada.; University of Toronto, Toronto, ON, Canada., Nguyen CV; Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Oza VS; The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA., Patel AB; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; University of Texas Health Science Center- Houston, Houston, TX, USA., Rotemberg V; Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shah SD; Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; School of Medicine, Case Western Reserve University, Cleveland, OH, USA., Zheng L; Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Miller CH; Galter Health Sciences Library and Learning Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Hlobik M; Dermatology Section, Division of Immunology, Boston Children's Hospital, Boston, MA, USA., Daigneault J; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Choi JN; Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA., Huang JT; Department of Dermatology, Harvard Medical School, Boston, MA, USA.; Dermatology Section, Division of Immunology, Boston Children's Hospital, Boston, MA, USA.; Department of Pediatrics, Harvard Medical School, Boston, MA, USA., Vivar KL; Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Division of Pediatric Dermatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Aug 23; Vol. 32 (9), pp. 610. Date of Electronic Publication: 2024 Aug 23.
DOI: 10.1007/s00520-024-08810-x
Abstrakt: Background: MEK inhibitors cause a wide spectrum of mucocutaneous toxicities which can delay or interrupt life-saving therapy.
Purpose: To summarize the morphology, incidence, and clinical presentation of mucocutaneous toxicities from MEK inhibitors via a scoping review of the literature.
Methods: We conducted a scoping review of the published literature, including clinical trials, retrospective and prospective studies, reviews, and case reports and series. All included literature was analyzed by a panel of pediatric and adult oncodermatologists.
Results: Of 1626 initial citations, 227 articles met final inclusion criteria. Our review identified follicular reactions, ocular toxicities, xerosis, eczematous dermatitis, edema, and paronychia as the most common mucocutaneous side effects from MEK inhibitor therapy. Grade 1 and 2 reactions were the most prevalent and were typically managed while continuing treatment; however, grade 3 toxicities requiring dose reductions or treatment interruptions were also reported.
Conclusion: Mucocutaneous toxicities to MEK inhibitor therapy are common and most often mild in severity. Early recognition and treatment can mitigate disruptions in oncologic therapy.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: